CTRI/2021/11/038321
Not yet recruiting
未知
Sentinel Surveillance for Adverse Events of Special Interest (AESI) following COVID-19 vaccination in India
John Snow India Private Limited0 sites0 target enrollmentTBD
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- John Snow India Private Limited
- Status
- Not yet recruiting
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Admitted for at least 24 hours
- •Diagnosis that meets any of the 11 index clinical conditions (AESIs)
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
A research study to collect long term safety information from subjects who have received study treatment from a qualifying lenabasum Corbus trial.Dermatomyositis (DM) is a rare and serious autoimmune disease.An overactive immune response causes chronic inflammation,which results in growth of scar tissue in the skin,muscles,and many internal organs.Cystic Fibrosis (CF) is a genetic disorder which results in thick mucus formation on the airways leading to increased lung infections,fibrosis of the lungs and digestive tract and abnormal immune functionMedDRA version: 20.0Level: PTClassification code 10012503Term: DermatomyositisSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersMedDRA version: 20.0Level: PTClassification code 10011762Term: Cystic fibrosisSystem Organ Class: 10010331 - Congenital, familial and genetic disordersTherapeutic area: Not possible to specifyEUCTR2020-001762-11-HUCorbus Pharmaceuticals, Inc.100
Active, not recruiting
Phase 1
A research study to collect long term safety information from subjects who have received study treatment from a qualifying lenabasum Corbus trial.EUCTR2020-001762-11-GBCorbus Pharmaceuticals, Inc.100
Active, not recruiting
Phase 1
A research study to collect long term safety information from subjects who have received study treatment from a qualifying lenabasum Corbus trial.Dermatomyositis (DM) is a rare and serious autoimmune disease.An overactive immune response causes chronic inflammation,which results in growth of scar tissue in the skin,muscles,and many internal organs.Cystic Fibrosis (CF) is a genetic disorder which results in thick mucus formation on the airways leading to increased lung infections,fibrosis of the lungs and digestive tract and abnormal immune functionMedDRA version: 20.0Level: PTClassification code 10012503Term: DermatomyositisSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersMedDRA version: 20.0Level: PTClassification code 10011762Term: Cystic fibrosisSystem Organ Class: 10010331 - Congenital, familial and genetic disordersTherapeutic area: Not possible to specifyEUCTR2020-001762-11-SECorbus Pharmaceuticals, Inc.100
Active, not recruiting
Phase 1
A research study to collect long term safety information from subjects who have received study treatment from a qualifying lenabasum Corbus trial.Dermatomyositis (DM) is a rare and serious autoimmune disease.An overactive immune response causes chronic inflammation,which results in growth of scar tissue in the skin,muscles,and many internal organs.Cystic Fibrosis (CF) is a genetic disorder which results in thick mucus formation on the airways leading to increased lung infections,fibrosis of the lungs and digestive tract and abnormal immune functionMedDRA version: 20.0Level: PTClassification code 10012503Term: DermatomyositisSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersMedDRA version: 20.0Level: PTClassification code 10011762Term: Cystic fibrosisSystem Organ Class: 10010331 - Congenital, familial and genetic disordersTherapeutic area: Not possible to specifyEUCTR2020-001762-11-DECorbus Pharmaceuticals, Inc.100
Completed
Not Applicable
Surveillance of adverse events associated with totally implanted venous-access portsISRCTN57640029French Ministry of Health and Sport (France)1,000